{"id":"bat2206","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BAT2206 functions as a bispecific monoclonal antibody designed to target dual immune pathways, likely involving PD-1 and LAG-3 or similar checkpoint molecules. By blocking inhibitory signals on T cells through multiple mechanisms simultaneously, the drug aims to overcome tumor immune evasion more effectively than single-checkpoint inhibitors, potentially improving anti-tumor immunity in solid tumors.","oneSentence":"BAT2206 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:31.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT04728360","phase":"PHASE3","title":"Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2021-07-06","conditions":"Plaque Psoriasis","enrollment":556},{"nctId":"NCT04371185","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2020-08-08","conditions":"Psoriasis","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BAT2206","genericName":"BAT2206","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAT2206 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}